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Crystal Structures of the Active and
Alloxanthine-Inhibited Forms of Xanthine
Dehydrogenase from Rhodobacter capsulatus
NAD than with O2 as their final electron acceptor, and
do not undergo conversion to the oxidase form [5].
The active mammalian enzyme is a homodimer with
a molecular mass of 290 kDa in which the two monomers
act as independent catalytic units. Each monomer con-
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scopically distinct [2Fe-2S] centers, and one FAD cofac-Stony Brook, New York 11794
2 Department of Biochemistry tor [6]. Upon substrate oxidation at the molybdopterin
center, electrons are transferred across the two [2Fe-Duke University Medical Center
Durham, North Carolina 27710 2S] clusters to the FAD where either NAD or molecular
oxygen is reduced [7].
In humans, urate, the ionized form of uric acid that
predominates at physiological pH, is the final product ofSummary
the XDH-catalyzed purine degradation and is excreted in
the urine. High circulating levels of uric acid (hyperuri-Xanthine dehydrogenase (XDH), a complex molybdo/
iron-sulfur/flavoprotein, catalyzes the oxidation of hy- cemia) can have severe effects due to the low solubility
of sodium urate. The XDH inhibitor allopurinol (1H-pyra-poxanthine to xanthine followed by oxidation of xan-
thine to uric acid with concomitant reduction of NAD. zolo[3,4-d] pyrimidin-4-ol; Figure 1) is a very common,
orally administered drug used to treat hyperuricemiaThe 2.7 A˚ resolution structure of Rhodobacter capsula-
tus XDH reveals that the bacterial and bovine XDH associated with chronic gout (gouty arthritis), cancer
chemotherapy, or hyperplastic or radiation therapy [8].have highly similar folds despite differences in subunit
composition. The NAD binding pocket of the bacterial It has also been used to aid in post ischemic reperfusion
injury caused partly by the formation of oxygen-derivedXDH resembles that of the dehydrogenase form of the
bovine enzyme rather than that of the oxidase form, free radicals from XO [9]. XDH (or XO), in the Mo(VI)
state, oxidizes allopurinol to alloxanthine (1H-pyrazolowhich reduces O2 instead of NAD. The drug allopuri-
nol is used to treat XDH-catalyzed uric acid build-up [3,4-d] pyrimidine-4,6-diol; also known as oxypurinol).
The reduced enzyme in the Mo(IV) state forms a tight,occurring in gout or during cancer chemotherapy. As
a hypoxanthine analog, it is oxidized to alloxanthine, inactive complex with alloxanthine, which blocks the
substrate binding site [10].which cannot be further oxidized but acts as a tight
binding inhibitor of XDH. The 3.0 A˚ resolution structure A well-characterized prokaryotic XDH with similar ac-
tivity to the eukaryotic form is the enzyme isolated fromof the XDH-alloxanthine complex shows direct coordi-
nation of alloxanthine to the molybdenum via a nitro- the phototrophic purple bacterium Rhodobacter capsu-
latus [11]. R. capsulatus XDH (RcXDH) is a cytoplasmicgen atom. These results provide a starting point for
the rational design of new XDH inhibitors. enzyme with an ()2 heterotetrameric structure and a
molecular mass of 275 kDa. The cofactors were identi-
fied to be located on two different polypeptides withIntroduction
the iron sulfur clusters and the FAD bound to the XDHA
subunit, and the molybdenum cofactor (Moco) boundXanthine oxidase/dehydrogenase (XO/XDH) is a com-
plex metallo-flavoprotein that catalyzes the oxidative to the XDHB subunit. In contrast, all three cofactors are
bound within a single subunit in eukaryotes. The aminohydroxylation of purines, pyrimidines, pterins, and alde-
hyde substrates (Figure 1). The term xanthine oxidase acid sequence of RcXDH has a high degree of similarity
to eukaryotic xanthine dehydrogenases/oxidases. Fur-(XO) was originally used to describe the enzyme from
bovine milk because of its well-established role in the thermore, analysis of the Moco in RcXDH revealed the
presence of molybdopterin (MPT), as found for all eu-conversion of hypoxanthine and xanthine to uric acid
and its ability to use O2 as an electron acceptor [1]. It karyotic Moco-containing enzymes. This is in contrast
to most bacterial molybdoenzymes in which the terminalis now known that the mammalian xanthine oxidizing
enzymes, including that from bovine milk [2] and rat liver phosphate of MPT is covalently attached to an addi-
tional nucleotide such as GMP or CMP to generate dif-[3, 4] are really dehydrogenases that transfer electrons
to NAD rather than to O2 in vivo, but can undergo a ferent dinucleotide forms of the cofactor.
The crystal structures of bovine milk xanthine dehy-dehydrogenase to oxidase conversion whereby they
lose the ability to use NAD as electron acceptor con- drogenase (bXDH) and xanthine oxidase (bXO) have re-
cently been solved at 2.1 A˚ and 2.5 A˚ resolution, respec-comitant with a nearly 10-fold increase in the oxidase
activity. In contrast, the avian enzymes are stable dehy- tively [12]. It was shown that during the conversion of
XDH to XO, a major structural rearrangement blocksdrogenases, displaying 50-fold higher activity with
access of NAD to its binding site near the FAD moiety
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Figure 1. Reactions Catalyzed by Xanthine
Dehydrogenase
(A) Hypoxanthine is converted to xanthine
and then to uric acid in the oxidative half-
reaction while the Mo center is reduced from
the VI to the IV state in each reaction.
The reductive half-reaction to reestablish the
Mo(VI) state is not shown.
(B) Inhibition by allopurinol. Allopurinol is con-
verted to alloxanthine, which is not further
oxidized by XDH, but binds tightly at the ac-
tive site of XDH when in the Mo(IV) state. The
atom-numbering scheme is indicated.
and changes the electrostatic environment of the bound code 1FO4 [12]) as a search model. The butterfly-shaped
heterotetramer has an accessible surface area ofFAD, reflecting the switch of substrate specificity ob-
served for the two forms of this enzyme. Despite the 79,682 A˚2 with overall dimensions of 155 A˚  100 A˚ 
70 A˚ (Figure 2A). The structure was refined at 2.7 A˚similarities to eukaryotic XDH enzymes, RcXDH, like
chicken XDH [13], is isolated with high reactivity toward resolution to an R factor of 0.215 with an Rfree of 0.252.
The enzyme crystallizes in space group P1 with twoNAD and low reactivity toward oxygen (0.2%) and
does not undergo conversion to the oxidase form (S.L., ()2 heterotetramers per asymmetric unit (a.s.u.), which
are related to each other by a 92.8 rotation. Each ofunpublished data).
This work presents the crystal structure of the active these heterotetramers is composed of two functionally
form of RcXDH at a resolution of 2.7 A˚, offering a struc- independent  heterodimers related by a 2-fold axis
tural basis for why the conversion of XDH to XO does of symmetry. This allowed the use of symmetry re-
not occur in RcXDH. Moreover, the structure of the allo- straints on the four similar heterodimers (chains AB, CD,
xanthine-RcXDH complex was solved, providing the first EF, and GH) in the a.s.u. throughout refinement. The
crystallographic insight into the mechanism of inhibition model has good overall stereochemistry with 87% of all
by alloxanthine. residues in the most favorable regions of the Ramachan-
dran diagram and only two residues (Tyr-A139 and Ser-
Results and Discussion B458) in disallowed regions as defined by PROCHECK
[14]. Both of these outliers are well defined in a-weighted
2Fo Fc electron density maps.Overall Structure
The crystal structure of XDH from the phototrophic pur- The small and large subunits of each heterodimer
have been termed XDHA and XDHB, respectively (Figureple bacterium R. capsulatus was solved by molecular
replacement (Table 1) using bXDH (Protein Databank 2A). The N-terminal iron/sulfur domain of XDHA (resi-
Table 1. Data Collection and Refinement Statistics
Native Alloxanthine Inhibited
Data Collection
Space group P1 P1
Unit cell dimensions
a, b, c (A˚) 92.9, 141.1, 158.1 92.6, 140.7, 157.7
, , 	 () 109.5, 105.8, 101.3 109.6, 105.8, 101.3
Resolution limits (A˚) 50.0–2.70 A˚ 30.0–3.00 A˚
Completeness (%) 99.2 99.1
Rsym 0.161 (0.730) 0.159 (0.741)
I
/I
 12.8 (2.7) 10.1 (2.1)
Refinement Statistics
Number of observed reflections 722,868 551,313
Number of unique reflections 187,987 135,608
Number of protein/cofactor atoms 36,486 36,505
Number of waters 125 4
Rcryst(Rfree) 0.215 (0.252) 0.195 (0.244)
Deviations from ideal values in
Bond lengths (A˚) 0.025 0.030
Bond angle distances () 2.365 2.751
Ramachandran Statistics 87.7/11.1/1.0/0.2 85.9/12.9/1.0/0.2
Rsym  hkli|Ii  I
|/hkliI
 where Ii is the ith measurement and I
 is the weighted mean of all measurements of I. I
/I
 indicates
the average of the intensity divided by its average standard deviation. Numbers in parentheses refer to the respective highest resolution data
shell in each data set.
Rcryst  ||Fo|  |Fc||/|Fo| where Fo and Fc are the observed and calculated structure factor amplitudes. Rfree same as Rcryst for 5% of the data
randomly omitted from the refinement. Ramachandran statistics indicate the fraction of residues in the most favored, additionally allowed,
generously allowed, and disallowed regions of the Ramachandran diagram, as defined by the program PROCHECK [14].
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Figure 2. Structure of RcXDH
(A) RcXDH forms an ()2 heterotetramer. The
XDHA subunits are drawn in light green and
light blue and the XDHB subunits in dark
green and dark blue. The N and C termini of
each subunit are labeled in their respective
colors with N and C. The [2Fe-2S] and FAD
cofactors of XDHA and the Moco of XDHB
are shown as space-filling models. In one het-
erodimer the cofactors are color coded with
the Fe in gray and the Mo in green. The latter
is hidden by the dithiolene sulfurs in this view.
(B) Superposition of the bXDH monomer (Pro-
tein Databank entry 1FO4) and the RcXDH
heterodimer. The polypeptides are shown as
C traces, with the RcXDH color coded and
in a similar orientation as in (A) and the bXDH
structure shown in gray. In the bXDH struc-
ture, the FAD and the Moco domain are con-
nected (linker shown as ribbon in magenta,
the sequence stretch between the two ma-
genta spheres is disordered), whereas in
RcXDH these domains are separated into two
subunits (C terminus of XDHA and N terminus
of XDHB shown as light and dark blue
spheres, respectively). This difference results
in a four-stranded sheet in the RcXDH struc-
ture (shown as blue ribbons) and a five-
stranded  sheet in the bXDH structure. The
three-stranded  sheet present in RcXDH, but
not in bXDH, is indicated as a blue ribbon.
The cofactors are shown in red (RcXDH) and
black (bXDH), connected by a dotted line.
Proteolytic sites of bXDH are indicated as
yellow triangles. This Figure and Figures 3, 5,
and 8 have been generated with the programs
MOLSCRIPT [48] and RASTER3D [49].
dues A1–A153) contains two [2Fe-2S] clusters and is lated in their primary sequences. Other members of this
attached to the C-terminal FAD binding domain (resi- family have been structurally characterized, including
dues A185–A462) through a 31 amino acid extended bXDH, aldehyde oxidoreductase from Desulfovibrio gi-
peptide linker. XDHB (residues B1–B777) is the Moco gas (ALO) [15], and CO Dehydrogenase from Oligotro-
binding subunit and the site of dimerization between pha carboxidovorans (COD) [16] with sequence identi-
heterodimers. It also contains the binding site for the ties to RcXDH of 39%, 30%, and 25%, respectively.
substrate from which two electrons are transferred to RcXDH shares high similarity with the bovine ortholog
the oxidized Mo(VI). The two [2Fe-2S] clusters constitute in terms of fold and arrangement of cofactors, in spite
a pathway for electron transfer to the FAD, the site of of the different number of subunits. Each subunit of
NAD reduction. The two active sites of the heterotet- bXDH, composed of the three cofactor binding regions,
ramer are 52 A˚ (Mo-Mo distance) apart with no other is equivalent to one RcXDH heterodimer, which lacks
cofactors in between, suggesting two independent cata- the linker between the FAD and Moco domains. The
lytic units. No electron density was observed for resi- RcXDH heterodimer and bXDH monomer can be super-
dues A167–A179 of the linker between the two domains imposed with an rms deviation of 1.25 A˚ for 1122 C
of XDHA and for residues B382–B397 of the Moco bind- atoms out of 1239. Figure 2B shows the connection of
ing subunit XDHB. the two domains in the monomeric bXDH in comparison
to heterodimeric RcXDH. The linker between the FAD
and Moco domain in bXDH forms the fifth strand of whatStructurally Related Proteins
is a four-stranded  sheet in RcXDH.RcXDH is a member of the xanthine oxidase family of
molybdopterin-containing enzymes, which are all re- ALO and COD are structurally similar to RcXDH as
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well. ALO is part of an electron transfer chain involving Leu-B421). The proteolytic sites in bXDH are located
after Leu-219 and Lys-569 (pancreatine cleavage) orthree other proteins and catalyzes the oxidation of alde-
hydes to carboxylic acids while COD catalyzes the oxi- after Lys-551 (tryptic cleavage) [12]. Both Lys-569 and
Lys-551 are located in the linker connecting the FADdation of CO to CO2 using H2O. ALO is a homodimeric
enzyme in which the monomer is analogous to the het- and Moco domains. In RcXDH, these connecting resi-
dues are not present since the domains form separateerodimer of RcXDH, but it lacks the FAD domain. COD,
a dimer of heterotrimers, contains all three cofactor subunits (Figure 2B). Apparently, the connection be-
tween the two domains is not required for XDH activity.binding domains on separate polypeptides [16]. It
should be noted that both of these proteins contain The proteolytic site after Leu-219 is located in the linker
between the iron/sulfur and FAD domains, which inthe molybdopterin cytosine dinucleotide rather than the
MPT form of the Moco. bXDH is 60 residues in length and is ordered before
conversion. In contrast, the corresponding linker in
RcXDH is 12 residues in length and is disordered.The FAD Domain of XDHA
The protein modifications that cause the conversionThe FAD domain of RcXDH shares only 22% sequence
to the XO form are distant from the FAD active site.identity to the FAD domain of bXDH but is structurally
Nevertheless, changes in redox potential [18] and struc-very similar with an rms deviation of 1.6 A˚ for 260 C
ture [12] are observed. Upon proteolytic cleavage, a 13-atoms out of 282. This domain can be divided into three
residue loop (424–436; A352–A364 in RcXDH), referredseparate subdomains (Figure 2A): the N-terminal subdo-
to as the “variable loop” hereafter, swings in front ofmain (A180–A225), the central subdomain (A226–A343),
the isoalloxazine ring of FAD, changes the electrostaticand the C-terminal subdomain (A344–A462). The N-ter-
environment, and sterically interferes with NAD bindingminal subdomain consists of a three-stranded parallel
[12]. We have compared the structure of the FAD center
 sheet bordered by twohelices. The bulk of the central
of RcXDH to that of the bovine enzyme in its XDH and XOsubdomain is made up of a five-stranded antiparallel 
form (Figure 3). Despite differences in primary sequencesheet surrounded by six short  helices. The C-terminal
(Figure 4A) and in the details of interactions, the variablesubdomain begins with a three-stranded antiparallel 
loop conformation observed in RcXDH superimposessheet followed by three  helices.
surprisingly well with that of the XDH form.The FAD molecule is bound deeply within the enzyme
Examination of the RcXDH structure suggests severalin an extended conformation (Figure 3). The FAD bind-
reasons for the absence of an XO form. The primarying domain contains the motifs A203AGGTDA207 and
sequence of the variable loop is only moderately con-A280TIGGA283 (Figure 4A), which are similar to the FAD
served in RcXDH and bXDH, but the sequences sharebinding site of the vanillyl-alcohol oxidase (VAO) family
a high content of charged residues (Figure 4A). In RcXDHof flavoproteins, making it a distant relative [17]. The
and in the XDH form of the bovine enzyme, these resi-two glycines and Thr-A206 of the first motif interact with
dues are engaged in salt bridges, whereas they are sol-the pyrophosphate moiety, while Asp-A207 is hydrogen
vent exposed in the XO form. Phe-A357 in RcXDH re-bonded to the ribose of the FMN segment of FAD. The
places Arg-427, one of the charged residues of theA280TIGGA283 motif creates a pocket for the adenosine and
bovine loop. Its side chain is part of a hydrophobiccontacts the pyrophosphate directly through main chain
patch that includes side chains of both XDHA and XDHB.hydrogen bonds. The isoalloxazine ring is solvent acces-
Presumably, disrupting these interactions and renderingsible at its si-side, while the re-side stacks onto Phe-
the hydrophobic side chain of Phe-A357 solvent acces-A270, Ala-A271 and Val-A275. All these residues are
sible in a XO-like conformation would be highly unfavor-type conserved from bacteria to mammals (Figure 4A).
able. In the bovine enzyme, Arg-427 interacts with Phe-Residues within the central subdomain and one residue
549, which is highly conserved in eukaryotic XDHs. Thisof the C-terminal domain form hydrogen bonds to the
residue is part of a loop that is cleaved and becomesisoalloxazine (Lys-A352 N to O4, Asp-A293 O2 to N3,
disordered in the conversion of bXDH to bXO. Moreover,Asn-A284 N2 and Asp-A293 N to O2). Each of these
some of the interactions of the bovine enzyme with theresidues is strictly conserved in all analyzed XDH se-
variable loop in its XO form would not be possible inquences as well as in COD. The methyl groups of the
RcXDH because the respective residues are not con-isoalloxazine ring are located in a hydrophobic pocket
served. For instance, Lys-433 interacts with Asp-360 informed by Gly-A42, Leu-A210, and Leu-A64.
the XO form of the bovine enzyme, while, in RcXDH, the
aspartate (A293) is conserved and Ala-A363 replaces
XDH to XO Conversion Lys-433.
Proteolytic cleavage or cysteine modification induces The conformational change of the variable loop is also
changes in the FAD active site of the bovine enzyme sterically inhibited by a second loop (interfering loop)
that prevent the reaction with NAD, but not with dioxy- from A422 to A431 in RcXDH (Figure 4A). Comparing
gen [1]. RcXDH has not been observed to lose its ability eukaryotic and bacterial primary sequences, this region
to react with NAD (S.L., unpublished data). Inspection is not well conserved, but there is high conservation
of the sequence and structure of RcXDH shows that the within each kingdom (Figure 4). Notably, the number
elements that trigger XDH to XO conversion in the bovine and position of Pro and Gly residues is different between
enzyme are not present in the bacterial enzyme. The kingdoms, with the eukaryotic XDH loop containing a
cysteines that are modified to convert XDH to XO are highly conserved Pro-Gly-Gly motif. Consequently, it is
not present in RcXDH (Cys-535 is replaced by Pro-A462, not surprising that the structure of the RcXDH interfering
loop and the corresponding loop in bXDH are dissimilar.the last residue in XDHA, while Cys-992 is replaced by
Crystal Structure of Xanthine Dehydrogenase
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Figure 3. The FAD Active Site
(A) Superposition of the FAD domains of RcXDH, bXDH, and bXO. RcXDH is shown in light blue, bXDH in gray and bXO (Protein Database
entry 1FIQ) in yellow. The variable loop that undergoes a conformational change upon conversion of bXDH to bXO is indicated by numbers
(K352 to V364 in RcXDH). Residues of RcXDH interacting with the cofactor are shown in all-bond representation and are indicated by numbers.
Dashed lines indicate hydrogen bonds.
(B) View 90 rotated compared to (A). A loop in RcXDH that may sterically hinder the conformational change of the variable loop is shown in
dark blue. Residues in RcXDH pointing toward the variable loop are shown in all bond representation. The corresponding residues in bXDH
are Ala and Pro and therefore do not interfere with the XDH to XO conversion.
The interfering loop of RcXDH is much closer to the FAD, ments, could also be present in solution as a mechanism
to move Ile-A361 away from the isoalloxazine ring. It isfilling the space that the variable loop would occupy in
its XO conformation. The large side chains of residues possible that the variable loop of XDH has to be inher-
ently flexible for enzymatic activity and that this flexibilityMet-A428 and Arg-A429 of the interfering loop in RcXDH
(corresponding to Ala-502 and Pro-503 in bXDH) occupy has evolved to allow conversion to XO in mammalian
enzymes.positions that would sterically clash with the variable
loop in a bXO-like conformation.
Structural studies on carbon monoxide dehydroge- The Iron/Sulfur Binding Domain of XDHA
The iron/sulfur domain of XDHA contains two [2Fe-2S]nase have shown that the central ring of the isoalloxa-
zine moiety is not completely solvent accessible be- cluster binding subdomains, which are highly conserved
when compared to their counterparts in bXDH, ALO,cause it is covered by an aromatic side chain [16]. It
has been suggested that this side chain protects the and COD. The iron/sulfur domains of bXDH and RcXDH
share 44% sequence identity and can be superimposedFAD from reacting with solvent but moves away when
the substrate NAD is present. In RcXDH, the variable with an rms deviation of 1.06 A˚ for 143 C atoms. Those
from ALO and COD have rms deviations of 1.6 A˚ for 147loop contains a conserved isoleucine (Ile-A361; Ile-431
in bXDH) at the corresponding position. It would interfere C atoms and 1.4 A˚ for 148 C atoms and sequence
identities of 38% and 41%, respectively. The geometrieswith the nicotinamide ring of NAD, assuming hydride
transfer in XDH proceeds while NAD binds face-to- as well as distances between the two [2Fe-2S] clusters
in all four proteins are surprisingly similar. Moreover,face to the isoalloxazine ring as observed in other fla-
voenzymes [19]. This pocket, which is formed by both many of the residues proximal to the clusters are either
identical or type conserved (Figure 5).the XDHA and XDHB subunits, is different in the four
copies related by noncrystallographic symmetry present The C-terminal subdomain comprises residues A75–
A153 and consists of a ferredoxin-type four-helix bundlein the crystal. While the respective domains (XDHB and
the two domains of XDHA) are similar to each other, with 2-fold symmetry. The [2Fe-2S] cluster is located at
its apex, which inserts into XDHB and seals the Mocodifferences exist in their relative orientation. The Moco
and FES domains appear tightly bound acting as one from solvent. This positions the closest iron to the Moco
5.4 A˚ from the exocyclic amino group and 14.9 A˚ fromrigid unit in each copy. Superimposing the Moco/FES
domains of each of the four molecules reveals a variable the Mo ion (Figure 5). The cluster is buried approximately
12 A˚ beneath the protein surface, thus rendering it inac-orientation of the FAD domain, leading to shifts of corre-
sponding atoms in the FAD domain of up to 1.1 A˚. This cessible to solvent. Cys-A103, Cys-A106, Cys-A134, and
Cys-A136 coordinate the iron atoms of the cluster. Themovement is of the hinge-type with the hinge being
located at the interface between the Moco and FAD S	 atom of Cys-A136 is positioned 3.6 A˚ from the exocy-
clic amine of the Moco. Hydrogen bonds are formed todomains and involving residues A356–A360 of the vari-
able loop and residues A272–A274. This domain reorien- the cluster sulfurs via backbone nitrogens.
The N-terminal subdomain includes residues A3–A74tation, probably caused by different crystal environ-
Structure
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Figure 4. Sequence Alignment of Selected Residues of XDH from Different Species
(A) Sequence stretches within XDHA. The first four residues (A41–A44 in R. capsulatus) belong to the first iron-sulfur domain, all other residues
are part of the FAD domain. Residues interacting with the FAD cofactor are highlighted in blue. The two lines above the sequence alignment
indicate residues that are signature motifs of the FAD binding site of the vanillyl-alcohol oxidase family of flavoproteins. The variable loop
and the interfering loop (see text) are indicated.
(B) Sequence stretches within the XDHB subunit. Residues highlighted in red interact with the Moco, while residues highlighted in green
participate in inhibitor binding. Glu-B730 interacts with both the molybdenum atom and the inhibitor alloxanthine.
and is very similar to plant-type [20] as well as cyanobac- sheet at approximately 30. Likewise, the Mo2 domain,
which supplies the majority of the interactions made toterial [21] [2Fe-2S] ferredoxins. The cluster is coordi-
nated through Cys-A39, Cys-A44, Cys-A47, and Cys- the Moco, consists of two subdomains. Each contains
a four-stranded mixed  sheet interacting with two A63. It is positioned adjacent to the 7, 8-methyl
groups of the flavin ring at the interface of the FAD and helices. The fold of XDHB is homologous to that of the
corresponding domains in bXDH, ALO, and COD withiron/sulfur domains. The closest iron is located 8.1 A˚
from the 7-methyl carbon and 12.4 A˚ from the closest the exception of an additional three-stranded  sheet
found only in COD and RcXDH (Figure 2B). This solvent-iron of the flanking cluster (Figure 5). The nature of the
electron transfer from the Moco to the FAD via the [2Fe- exposed  sheet is at a distance from both the electron
transfer path and intersubunit interfaces and its function2S] clusters remains uncertain. A “through-space”
mechanism has been proposed based on the fact that is unclear at present.
RcXDH utilizes the molybdopterin (MPT) form of thethe distances between the cofactors are less than 14 A˚
[22]. Interestingly, there is a conserved water molecule Moco, which is the form present in all eukaryotic molyb-
doenzymes. It is composed of two fused ring systems:in all four structures positioned 6.0 A˚ from the closest
iron of the Moco-proximal cluster and 6.6 A˚ from the a bicyclic pterin and a monocyclic pyran. The solvent
inaccessible Moco is buried between the Mo1 and Mo2closest iron of the FAD-proximal cluster in the RcXDH
model (Figure 5). Whether this water molecule plays a domains and is positioned near the XDHA-XDHB inter-
face in its typical bent conformation as seen in the otherrole in electron transfer is not known.
Moco-containing enzymes [23, 24].
The Moco is tightly bound by the protein through inter-The Moco Subunit (XDHB)
XDHB can be subdivided into the Mo1 domain (residues actions that are highly conserved (Figures 4B and 6). It
is coordinated via seven side-chain and seven main-B1–B411) and the Mo2 domain (residues B412–B777).
The Mo1 domain appears to be organized into two sub- chain hydrogen bonds. The only direct contact from
XDHA to the cofactor is formed between O1 of Gln-domains, each with substantial  sheet structure (Figure
2A). The first contains a seven-stranded mixed incom- A102 and the Moco N2. All other interactions, including
the hydrophobic stacking of Phe-B228 with the bicyclicplete  barrel partially wrapping a central  helix. The
second is composed of a five-stranded mixed  sheet pterin, originate from XDHB. The enzyme is active under
crystallization conditions as shown by spectrophoto-adjacent to two  helices that cross the back of the
Crystal Structure of Xanthine Dehydrogenase
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Figure 5. Superposition of the Iron/Sulfur Proximal Regions of RcXDH (Cyan), bXDH (Blue), ALO (Green), and COD (Red)
Side chains in gray represent strictly conserved side chains while those in cyan are type conserved. Black spheres symbolize strictly conserved
glycines. Selected distances and residues are labeled. Cofactors and side chains shown are from the RcXDH model.
metric analysis (data not shown), suggesting that it is The phosphate of the cofactor is bound via two hydro-
gen bonds, but, interestingly, there is no positivelyin the oxidized form with a Mo(VI) center. Difference
density maps identify three ligands attached to the Mo charged side chain in close proximity to stabilize the
negatively charged oxygens.ion in addition to the two dithiolene sulfurs. Two of these
ligands appear to be almost in plane with the dithiolene Access to the molybdenum center is possible only
through a narrow, rectangular opening in XDHB withand one axial. However, our current resolution is not
high enough to determine their chemical nature. Identi- dimensions of approximately 5 A˚ (length) 3 A˚ (width)
5 A˚ (depth), a perfect geometry for small planar mole-ties were inferred based on previous reaction mecha-
nism studies and analogy to the bovine [12] as well cules like xanthine (Figure 7). The bottom of the pocket
is lined by the molybdenum with its hydroxo ligand andas the D. gigas ALO Mo center [25]. The three ligands
assigned were one oxo and one hydroxo or water ligand by the side chain carboxylate of Glu-B730. The rectan-
gular sides of the pocket are lined by charged residuesin the dithiolene plane and one double-bonded sulfur
atom in the axial position. In addition to these five li- Glu-B232 and Arg-B310 on the short edges and hy-
drophobic residues Phe-B344 and Phe-B459 on the longgands, O2 of Glu-B730, at an average distance of 2.7 A˚
from the metal (individual values range from 2.5 to 3.0 A˚), edges. Two additional hydrophobic residues, Leu-B303
and Leu-B461, define the top. The asymmetric form ofis in close contact to the Mo. The hydroxo or water
ligand (O1) is putatively transferred to the substrate and the binding pocket and the pattern of hydrophobic and
charged side chains appears well suited to accommo-replenished to the Mo by a solvent water molecule [26].
Figure 6. Schematic Representation of Pro-
tein-Moco Interactions
Dashed lines indicate hydrogen bonds. In ad-
dition, the aromatic side chain of Phe-B228
stacks with the pterin rings (not shown).
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Figure 7. Access of Substrates to the Moco
Active Site
The molecular surface of RcXDH is rendered
transparently in gray. The side chain of Leu-
B461 was omitted from the surface calcula-
tion to afford a better view into the binding
pocket. Selected side chains lining the pocket
are shown in all-bond representation and la-
beled. The protein backbone is shown as a
yellow worm and the molybdopterin as ball-
and-stick. Figure drawn with SPOCK [50].
date planar molecules containing 5- or 6-membered the inhibitor (Figures 4B and 7). Alloxanthine occurs in
different tautomeric states at neutral pH [27]. In orderrings that are able to form hydrogen bonds or salt-brid-
to interact productively with Glu-B232 and Arg-B310,ges with Glu-B232 and Arg-B310. Apart from dictating
respectively, the N1-C6  O6 moiety would have to bethe planar shape, these interactions might also facilitate
in the enol form, whereas the N3-C2  O2 moiety wouldthe oxidation reaction by polarizing electrons of conju-
have to be in the keto or deprotonated enol form (refergated double bonds in the substrates.
to Figure 1 for atom numbering). The two charged resi-
dues are well conserved among the XDH sequencesAlloxanthine-Inhibited XDH
from different bacterial and eukaryotic species (FigureClinically, allopurinol is used to inhibit human XDH in
4B). Both nitrogens of the 5-membered ring are involvedpatients suffering from high levels of urate. Studies with
in interactions. N9 (presumably as NH) hydrogen bondsbXDH have shown that allopurinol is first oxidized by
to Glu-B730. N8 is so close to the molybdenum (2.1 A˚)XDH to alloxanthine [6], which then binds to the reduced
that it replaces the hydroxo ligand in plane with theform of the enzyme, thus inhibiting it (Figure 1). We
dithiolene moiety of the molybdopterin. The resultinghave incubated RcXDH with an excess of allopurinol
coordination sphere (one oxo ligand, one nitrogen li-and cocrystallized the resulting complex. To verify that
gand, and one axial sulfo ligand in addition to the twoRcXDH turns over allopurinol and remains bound to allo-
sulfurs of the dithiolene moiety) has been suggested forxanthine under the chosen crystallization conditions,
the alloxanthine complex of bXO based on combinedexcess allopurinol was removed by gel filtration, the
data from EPR, EXAFS, and ENDOR studies [28–31]. In
protein was denatured by heat, and the extract analyzed
contrast to the interaction of the molybdenum ion with
by reversed phase HPLC. The results clearly demon-
N8 of alloxanthine observed here, alloxanthine uses the
strate that alloxanthine is bound to RcXDH during the N9 atom for metal coordination and is protonated at N8
inactivation process (Figure 8A). The crystals of the en- in model transition metal complexes [32].
zyme inhibitor complex are isomorphous to those of The active site and interactions of bXDH and RcXDH
the active enzyme, which allowed the use of difference with the Moco are fundamentally identical. A notable
Fourier techniques to solve the structure. An extended exception is that in the Bovine model, O2 of Glu-A1261
difference density feature was observed in the substrate and Glu-B1261 are positioned 3.65 and 3.45 A˚ from the
binding site (Figure 8B), which has the shape of a planar molybdenum ion, respectively, whereas in the RcXDH
molecule and fills up most of the binding pocket. Inter- model, the distances range from 2.5 to 3.0 A˚. Addition-
estingly, it extends to the position of the hydroxo ligand ally, an extra hydrogen bond is made between the 	
of the molybdenum. In addition, a smaller difference oxygen of Ser-1082 (Gly-B532 in RcXDH) and the O1P
density peak is located at one side of the binding pocket phosphate oxygen of the Moco in the bovine enzyme.
near Glu-B730 and Arg-B310. Both allopurinol and allo- This high degree of similarity allows a direct comparison
xanthine have been modeled into the difference density. to be made of the alloxanthine complex of RcXDH with
The fit achieved with alloxanthine is superior, which is the salicylate-bound bXDH. The respective ligands oc-
in agreement with the biochemical data showing that cupy different but partially overlapping locations and
RcXDH oxidizes allopurinol and alloxanthine remains share some, but not all, interactions (Figure 8C). Notably,
bound to the protein. the bound salicylate molecule is located at the far end
In the resulting crystallographic model of RcXDH in of the substrate binding pocket and does not interact
complex with alloxanthine, numerous interactions exist with the Moco. Furthermore, Glu-802 in bXDH (corre-
between the protein and the inhibitor (Figure 8B). Func- sponding to Glu-B232 in RcXDH) does not bind to the
tional groups of the 6-membered ring of alloxanthine salicylate but rather faces the hydrophobic part of the
interact with Glu-B232, Arg-B310, and, via a water mole- 6-membered ring. The carboxylate of salicylate interacts
cule, with Glu-B730. Each of these residues is highly with Arg-880 (Arg-B310 in RcXDH) and with a water
conserved as are Phe-B344 and Phe-B459, which are molecule occupying almost the same location as the
water molecule found in the binding pocket of RcXDH.involved in face-to-face and edge-to-face contacts with
Crystal Structure of Xanthine Dehydrogenase
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Figure 8. Inhibition of the Moco Active Site
(A) Reversed phase HPLC elution profile of
the tightly bound inhibitor of allopurinol-
treated RcXDH (red line) compared to that of
a mixture of standards. HX, hypoxanthine; X,
xanthine; AP, allopurinol; AX, alloxanthine.
(B) Fo  Fc difference electron density con-
toured at 4  (red mesh) obtained from crys-
tals of allopurinol-incubated RcXDH shows
RcXDH inhibited by alloxanthine. The density
was calculated before introducing the inhibi-
tor into the crystallographic model to avoid
model bias and was averaged over all four
active sites present in the a.s.u. to increase
the signal to noise ratio. Residues interacting
with the inhibitor are shown in all-bond repre-
sentation and are indicated by numbers. The
molybdenum and its sulfo and oxo ligand are
shown as green, yellow and red (partially hid-
den in this view) spheres, respectively.
(C) Comparison of alloxanthine-RcXDH inter-
actions with salicylate-bXDH interactions.
The carbon atoms of the salicylate and of
bXDH are shown in cyan. Numbers in paren-
theses refer to bXDH. The molybdenum coor-
dination shown is that of the salicylate-bXDH
structure, with the oxo and hydroxo/aquo li-
gands shown as red spheres. The latter ligand
is replaced by N8 of alloxanthine in the allo-
xanthine-RcXDH structure.
Thus, the two carboxylate oxygens of salicylate have progressive renal failure [35]. Although new as well as
previously known compounds have recently been dis-the same ligands as N1 and O2 of alloxanthine, with the
solvent water able to serve as hydrogen bond donor or covered to inhibit XO/XDH activity [36], a clinically effec-
tive inhibitor has not been developed to treat hyperuri-acceptor. Finally, the hydroxyl of salicylate is bound to
Thr-1010, which is conserved in RcXDH, but does not cemia since allopurinol was introduced for patient use
in 1963 [37]. The crystal structure of RcXDH with alloxan-interact with alloxanthine.
thine bound advances our understanding of XDH/XO
inhibition by allopurinol, revealing its direct coordinationBiological Implications
to the Mo ion of the Moco. The high structural and
sequence similarity between RcXDH and its mammalianWe have solved the first structure of a bacterial xanthine
counterpart bXDH, especially in their respective activedehydrogenase. Despite differences in subunit compo-
sites, will allow these data to aid in the design of new,sition, the overall structure of bacterial RcXDH and the
more effective clinical inhibitors.mammalian bXDH are surprisingly similar, but differ in
important details. This includes the regions necessary
for XDH to XO conversion in bXDH, a process not ob- Experimental Procedures
served in RcXDH. Interestingly, sequence stretches
Expression and Purification of R. capsulatus XDHallowing this conversion are strictly conserved in eukary-
in E. coli Cellsotes, as are sequence stretches in prokaryotes that ap-
The genes encoding RcXDH, designated xdhABC, were isolated
pear to inhibit this conformational change in RcXDH. It from the R. capsulatus genome as described [11]. Using the pub-
has been proposed that, in mammals, the presence of lished gene sequences, primers were designed to allow cloning of
xdhABC into the NdeI and HindIII sites of the expression vectorXO in milk has a beneficial bactericidal effect [33]. Taking
pTrcHis [38] to yield pSL207, which expresses a His-tagged versioninto account that the chicken enzyme is also not con-
of XDH. For heterologous expression in E. coli, pSL207 was trans-verted to the XO form, it is possible that the ability of XDH
formed into E. coli TP1000 cells [39], which contain a deletion into be converted to XO has emerged through divergent
the mobAB genes responsible for Moco dinucleotide formation. For
evolution in mammals but not in other organisms. expression, 2 1 liter cultures of TP1000 cells carrying plasmid
Because of the high structural similarity of RcXDH pSL207 were grown at 30C in LB medium supplemented with 100
g/ml ampicillin, 1 mM molybdate, and 0.02 mM isopropyl--D-and bXDH, the bacterial enzyme is a good model system
thiogalactopyranoside (IPTG) until OD600  1. This culture was thenfor studying the mechanism of drug action. Allopurinol
transferred to two bottles containing 17 liters of supplemented LBhas been widely used for the clinical control of uric acid
medium and subsequently grown aerobically at 30C. After 18–20production in conditions of hyperuricemia. However, al-
hr, cells were harvested by centrifugation at 5000 g. The cell pellet
lopurinol toxicity and a severe life-threatening toxicity was resuspended in 8 volumes of 50 mM sodium phosphate, 300 mM
syndrome [34] have been reported in some patients, NaCl, pH 8.0, and, for cell lysis, a Microfluidics M110L Microfluidizer
Processor was used. Complete cell lysis was achieved by threeleading to eosinophilia, vasculitis, rash, hepatitis, and
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passages through a 112 M interaction chamber at 16,000–18,000 with similar unit cell dimensions (a  92.62 A˚, b  140.7 A˚, c 
157.7 A˚,   109.6,   105.8, and 	  101.3) as the untreatedpsi. After cell lysis, DNaseI was added and the lysate was incubated
for 30 min at room temperature. After centrifugation at 17,000  RcXDH crystals, allowing difference Fourier methods to be used for
the calculation of electron density maps. The model described hereg for 25 min, imidazole was added to the supernatant to a final
concentration of 10 mM. The supernatant was combined with 2 ml is from a 3.0 A˚ data set collected at beam line X4A at the National
Synchrotron Light Source. Data were processed with the HKL suite.of Ni2-nitriloacetic acid resin (Qiagen) per liter of cell growth, and
the slurry was equilibrated with gentle stirring at 4C for 30 min. The Refinement was performed using REFMAC keeping the same reflec-
tions as in the native data set to calculate the free R factor.slurry was poured into a column and washed with 2 column volumes
of 10 mM imidazole, 50 mM sodium phosphate, 300 mM NaCl, pH
8.0, followed by a wash with 10 column volumes of the same buffer Chromatographic Analysis of Allopurinol-Treated XDH
with 20 mM imidazole. The His-tagged XDH was eluted with 100 Ten milligrams of RcXDH in 0.5 ml reservoir solution with 6 mM
mM imidazole in 50 mM sodium phosphate, 300 mM NaCl, pH 8.0. allopurinol was incubated for 30 min at room temperature. Excess
Fractions containing XDH were combined and dialyzed against 50 allopurinol and free alloxanthine were separated from the protein
mM Tris, 1 mM EDTA, 2.5 mM dithiothreitol (DTT), pH 7.5. The by gel filtration using a PD10 column equilibrated with 50 mM Tris,
dialyzed sample was applied to a Q-Sepharose FPLC column and 1 mM EDTA, pH 7.5. Bound inhibitor was released from the enzyme
eluted with a linear gradient of 0–250 mM NaCl. To the pool of by heat treatment for 5 min at 95C. After removal of denatured
fractions containing XDH, 15% ammonium sulfate was added and protein by centrifugation for 5 min at 15,000 rpm, 100 l of the
the protein was then applied to a phenyl sepharose column equili- supernatant was chromatographed on a Hypersil ODS (5 M) HPLC
brated with 50 mM Tris, 1 mM EDTA, 2.5 mM DTT, 15% ammonium column equilibrated with 50 mM phosphate buffer (pH 5.5), 3%
sulfate, pH 7.5. XDH was eluted from the column with a linear gradi- methanol (1 ml/min) [47]. Eluted compounds were detected at 254
ent of 15%–0% ammonium sulfate. During purification, fractions nm and identified by comparing retention times and UV spectra
were monitored using SDS-PAGE, while enzyme activity was mea- with those of hypoxanthine, xanthine, alloxanthine, and allopurinol
sured spectrophotometrically by the reduction of nicotinamide ade- standards.
nine dinucleotide (NAD) as described earlier [11]. The yield of pro-
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